Ono Pharmaceutical (OPHLF) to Announce Earnings on Friday

Ono Pharmaceutical (OTCMKTS:OPHLFGet Free Report) is projected to issue its resultson Friday, July 31st. Analysts expect Ono Pharmaceutical to announce earnings of $0.25 per share and revenue of $679.8910 million for the quarter.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS:OPHLF opened at $14.61 on Wednesday. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10. The stock has a market cap of $6.87 billion, a PE ratio of 14.76 and a beta of 0.34. The stock’s fifty day simple moving average is $14.33 and its two-hundred day simple moving average is $14.76. Ono Pharmaceutical has a 1-year low of $10.27 and a 1-year high of $18.67.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Read Our Latest Report on OPHLF

About Ono Pharmaceutical

(Get Free Report)

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.

See Also

Earnings History for Ono Pharmaceutical (OTCMKTS:OPHLF)

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.